Please assess the completion status of the following clinical trial:

Trial Title: Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 2 diabetes with cardiovascular risk factors (\*) who treated with diet, exercise or antidiabetic medications~* Patients who were treated with statins for 8 weeks or longer~* Patients with low-density lipoprotein cholesterol equal to or greater than 100 mg/dL in the at least one of three measurements after the administration of statins~* Patients with glycerated hemoglobin (HbA1c, NGSP) equal to or greater than 6.0 % (7.0 % if patients were not treated with dipeptidyl-peptidase 4 inhibitors) and lesser than 10.5 %~(\*) cardiovascular risk factors were any of following conditions~1. Presence of stenosis (\>=25%) or plaque on the previous coronary angiography or coronary CT~2. Presence of coronary calcification on the previous coronary CT~3. History of acute coronary syndrome~4. History of percutaneous coronary intervention or coronary artery bypass graft~5. History of stroke (ischemic stroke or hemorrhagic stroke)~6. History of transient ischemic attack~7. History of peripheral artery diseases or aortic disorders~8. Ankle-Brachial Index (AMI) equal to or less than 0.9 in the past measurement~9. Presence of carotid artery plaque (including Max IMT \>=1.1mm) on carotid ultrasonography in the past~Exclusion Criteria:~* Patients with type 1 diabetes~* Patients with triglyceride equal to or greater than 400 mg/dL in the previous fasting measurements~* Patients with pregnancy, possible pregnancy, or on breast-feeding~* Patients with severe infections, perioperative status, or severe trauma~* Patients with renal dysfunction (creatinine \>= 2.4 mg/dl for men, \>= 2.0 mg/dl for women)~* Patients who were received glucagon-like peptide-1receptor agonists~* Patients whom physician in charge considered inappropriate for the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anagliptin (Type: ACTIVE_COMPARATOR): Anagliptin 100 mg bid for 52 weeks. Can increase to 200 mg bid if needed.
- Sitagliptin (Type: ACTIVE_COMPARATOR): Sitagliptin 50 mg qd for 52 weeks. Can increase to 100 mg qd if needed

Based on this trial design, predict the completion outcome and termination type (if applicable).